Synopsis of recent research by authors named "Ian Friedland"
- Ian Friedland's recent research primarily focuses on the development and evaluation of new antimicrobial therapies targeting multidrug-resistant infections, particularly among gram-negative pathogens such as carbapenem-resistant Enterobacteriaceae.
- His studies include phase 1 and phase 3 trials assessing the safety, tolerability, and effectiveness of novel agents like PLG0206, ceftolozane-tazobactam, and plazomicin in treating various complicated infections, highlighting their pharmacokinetics and antimicrobial activity.
- Friedland emphasizes the urgent need for innovative antibacterial treatments due to rising antimicrobial resistance and advocates for regulatory frameworks that facilitate the development and market entry of new antibiotics.